181 related articles for article (PubMed ID: 3465666)
1. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis.
Malesci A; Tommasini MA; Bonato C; Bocchia P; Bersani M; Zerbi A; Beretta E; Di Carlo V
Gastroenterology; 1987 Jan; 92(1):60-7. PubMed ID: 3465666
[TBL] [Abstract][Full Text] [Related]
2. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M
Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
[TBL] [Abstract][Full Text] [Related]
3. Values of CA 19-9 in the serum, pure pancreatic juice, and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor.
Tatsuta M; Yamamura H; Iishi H; Ichii M; Noguchi S; Yamamoto R; Okuda S
Cancer; 1985 Dec; 56(11):2669-73. PubMed ID: 3863691
[TBL] [Abstract][Full Text] [Related]
4. CA 19-9 in serum and pancreatic juice: its role in the differential diagnosis of resectable pancreatic cancer from chronic pancreatitis.
Malesci A; Evangelista A; Mariani A; Bersani M; Bonato C; Basilico M; Montorsi M; Beretta E
Int J Pancreatol; 1988; 3 Suppl 1():S119-23. PubMed ID: 3209865
[TBL] [Abstract][Full Text] [Related]
5. Significance of adenocarcinoma-associated antigen YH206 levels in the pancreatic juice.
Imai K; Ban T; Endo T; Hinoda Y; Sugiyama T; Hirane T; Yabana T; Hirata K; Wada T; Yachi A
Gastroenterol Jpn; 1990 Feb; 25(1):112-6. PubMed ID: 2407594
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody defines CA 19-9 in pancreatic juices and sera.
Schmiegel WH; Kreiker C; Eberl W; Arndt R; Classen M; Greten H; Jessen K; Kalthoff H; Soehendra N; Thiele HG
Gut; 1985 May; 26(5):456-60. PubMed ID: 3858206
[TBL] [Abstract][Full Text] [Related]
7. Serum CA 19-9 concentrations and computed tomography findings in patients with pancreatic carcinoma.
Sakahara H; Endo K; Nakajima K; Nakashima T; Koizumi M; Ohta H; Hidaka A; Kohno S; Nakano Y; Naito A
Cancer; 1986 Apr; 57(7):1324-6. PubMed ID: 3456252
[TBL] [Abstract][Full Text] [Related]
8. DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease.
Mahvi DM; Seigler HF; Meyers WC; Kalthoff H; Schmiegel WH; Metzgar RS
Pancreas; 1988; 3(4):488-93. PubMed ID: 3174610
[TBL] [Abstract][Full Text] [Related]
9. Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases.
Schmiegel WH; Eberl W; Kreiker C; Kalthoff H; Bützow GH; Jessen K; Klapdor R; Soehendra N; Wargenau M; Classen M
Hepatogastroenterology; 1985 Jun; 32(3):141-5. PubMed ID: 2410346
[TBL] [Abstract][Full Text] [Related]
10. Tumour antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma.
Hyöty M; Hyöty H; Aaran RK; Airo I; Nordback I
Eur J Surg; 1992 Mar; 158(3):173-9. PubMed ID: 1356458
[TBL] [Abstract][Full Text] [Related]
11. [The contribution of CA 19-9 in the differential diagnosis between chronic pancreatitis and cancer of the pancreas].
Van Gossum M; Delanghe A; Gerard M; Delcourt A; Deltenre M
Acta Gastroenterol Belg; 1987; 50(1):91-4. PubMed ID: 3480672
[No Abstract] [Full Text] [Related]
12. [The tumor markers CA 19.9, Ca 50 and CEA in the differential diagnosis of pancreatic carcinoma].
Röthlin M; Metzger U; Joller H; Largiadèr F
Schweiz Med Wochenschr; 1988 Jun; 118(24):924-9. PubMed ID: 2456610
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis.
Gentiloni N; Caradonna P; Costamagna G; D'Ostilio N; Perri V; Mutignani M; Febbraro S; Tinari N; Iacobelli S; Natoli C
Am J Gastroenterol; 1995 Jul; 90(7):1069-72. PubMed ID: 7611198
[TBL] [Abstract][Full Text] [Related]
14. Carcinoembryonic antigen (CEA) activity in pancreatic juice of patients with pancreatic carcinoma and pancreatitis.
Sharma MP; Gregg JA; Loewenstein MS; McCabe RP; Zamcheck N
Cancer; 1976 Dec; 38(6):2457-61. PubMed ID: 1000475
[TBL] [Abstract][Full Text] [Related]
15. CA 19-9 and pancreatic adenocarcinoma.
Safi F; Beger HG; Bittner R; Büchler M; Krautzberger W
Cancer; 1986 Feb; 57(4):779-83. PubMed ID: 3455839
[TBL] [Abstract][Full Text] [Related]
16. CA 19-9 in the differential diagnosis between pancreatic cancer and chronic pancreatitis.
Farini R; Fabris C; Bonvicini P; Piccoli A; del Favero G; Venturini R; Panucci A; Naccarato R
Eur J Cancer Clin Oncol; 1985 Apr; 21(4):429-32. PubMed ID: 3859414
[TBL] [Abstract][Full Text] [Related]
17. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.
Paganuzzi M; Onetto M; Marroni P; Barone D; Conio M; Aste H; Pugliese V
Cancer; 1988 May; 61(10):2100-8. PubMed ID: 2834038
[TBL] [Abstract][Full Text] [Related]
18. The distribution and localization of the monoclonal antibody-defined antigen 19-9 (CA19-9) in chronic pancreatitis and pancreatic carcinoma. An immunohistochemical study.
Makovitzky J
Virchows Arch B Cell Pathol Incl Mol Pathol; 1986; 51(6):535-44. PubMed ID: 2878526
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic significance of cancer-associated carbohydrate antigen (CA19-9) concentrations in pancreatic juice: analysis in pure pancreatic juice collected by endoscopic aspiration and immunohistochemical study in chronic pancreatitis.
Wakabayashi T; Sawabu N; Takemori Y; Satomura Y; Kidani H; Ohta H; Watanabe H; Yamakawa O; Takahashi H; Watanabe K
Pancreas; 1993 Mar; 8(2):151-9. PubMed ID: 8460089
[TBL] [Abstract][Full Text] [Related]
20. [Importance of the tumor-associated antigen CA 19-9 in the differential diagnosis of pancreatic diseases].
Heptner G; Domschke S; Schneider MU; Domschke W
Dtsch Med Wochenschr; 1985 Apr; 110(16):624-8. PubMed ID: 3857159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
